학술논문
Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease
Document Type
article
Author
Mbala-Kingebeni, Placide; Pratt, Catherine; Ruffin, Mbusa Mutafali; Pauthner, Matthias G; Bile, Faustin; Ndaye, Antoine Nkuba; Black, Allison; Lusamaki, Eddy Kinganda; Faye, Martin; Aziza, Amuri; Diagne, Moussa M; Mukadi, Daniel; White, Bailey; Hadfield, James; Gangavarapu, Karthik; Bisento, Nella; Kazadi, Donatien; Nsunda, Bibiche; Akonga, Marceline; Tshiani, Olivier; Misasi, John; Ploquin, Aurelie; Epaso, Victor; Paka, Emilia Sana; N’kasar, Yannick Tutu Tshia; Mambu, Fabrice; Edidi, Francois; Matondo, Meris; Bula, Bula; Diallo, Boubacar; Keita, Mory; Belizaire, Marie Roseline Darnycka; Fall, Ibrahima Soce; Yam, Abdoulaye; Sabue, Mulangu; Rimion, Anne W; Salfati, Elias; Torkamani, Ali; Suchard, Marc A; Crozier, Ian; Hensley, Lisa; Rambaut, Andrew; Faye, Ousmane; Sall, Amadou; Sullivan, Nancy J; Bedford, Trevor; Andersen, Kristian G; Wiley, Michael R; Ahuka-Mundeke, Steve; Tamfum, Jean-Jacques Muyembe
Source
New England Journal of Medicine. 384(13)
Subject
Language
Abstract
During the 2018-2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus-based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)-specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We initiated epidemiologic and genomic investigations that showed that the patient had had a relapse of acute EVD that led to a transmission chain resulting in 91 cases across six health zones over 4 months. (Funded by the Bill and Melinda Gates Foundation and others.).